GAL and neoplasm: The in vivo anti-Gal/α-gal epitope interaction provides the possibility of harnessing the immunologic potential of this antibody in a number of α-gal-associated therapies in several clinical settings, including the accelerated scar-free regeneration of injuries in the skin [46,47,48], the regeneration of injured ischemic myocardium following myocardial infarction [49,50], the regeneration of injured spinal cord [50,51] and the conversion of self-TAs into anti-tumor vaccines, which are discussed in the present review.